These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30116872)

  • 1. Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.
    Li PF; Mao YZ; Bai B; Gao Y; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
    Ann Hematol; 2018 Dec; 97(12):2381-2389. PubMed ID: 30116872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
    Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
    Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
    Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
    J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
    Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
    Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
    Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
    Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
    Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
    Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
    Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
    Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
    Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
    Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
    Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features.
    Jeon YK; Kim JH; Sung JY; Han JH; Ko YH;
    Hum Pathol; 2015 Jul; 46(7):981-90. PubMed ID: 25907865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
    Feng Y; Jing C; Yu X; Cao X; Xu C
    Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of cell-free Epstein-Barr virus DNA in the plasma of patients with peripheral T-cell and NK-cell lymphomas and peripheral T-cell proliferative diseases.
    Suwiwat S; Pradutkanchana J; Ishida T; Mitarnun W
    J Clin Virol; 2007 Dec; 40(4):277-83. PubMed ID: 17996493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological analysis of the age-related differences in patients with Epstein-Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders.
    Takahashi E; Ohshima K; Kimura H; Hara K; Suzuki R; Kawa K; Eimoto T; Nakamura S;
    Histopathology; 2011 Oct; 59(4):660-71. PubMed ID: 22014047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
    Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
    Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy.
    Wang ZY; Liu QF; Wang H; Jin J; Wang WH; Wang SL; Song YW; Liu YP; Fang H; Ren H; Wu RY; Chen B; Zhang XM; Lu NN; Zhou LQ; Li YX
    Blood; 2012 Sep; 120(10):2003-10. PubMed ID: 22826562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell receptor (TCR) phenotype of nodal Epstein-Barr virus (EBV)-positive cytotoxic T-cell lymphoma (CTL): a clinicopathologic study of 39 cases.
    Kato S; Asano N; Miyata-Takata T; Takata K; Elsayed AA; Satou A; Takahashi E; Kinoshita T; Nakamura S
    Am J Surg Pathol; 2015 Apr; 39(4):462-71. PubMed ID: 25634749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma].
    Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):462-468. PubMed ID: 32654458
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
    Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
    Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma.
    Kim HS; Ryu KJ; Ko YH; Kim HJ; Kim SH; Kim WS; Kim SJ
    Hematol Oncol; 2017 Sep; 35(3):310-316. PubMed ID: 26928433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.